| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/31/2008 | US20080025984 Combination Therapy Comprising Cloretazine |
| 01/31/2008 | US20080025983 Methods of screening based on the EGF receptor crystal structure |
| 01/31/2008 | US20080025982 Uses of Sperm Membrane Protein Obf |
| 01/31/2008 | US20080025981 Cancer-linked genes as targets for chemotherapy |
| 01/31/2008 | US20080025980 which binds to B lymphoblastoid cells and induces proliferation and activation of peripheral blood lymphocytes; anti-tumor effect when injected into a tumor-bearing subject; HIV infection or AIDS (Acquired Immune Deficiency Syndrome) |
| 01/31/2008 | US20080025979 Programmed Death 1(PD-1); bispecific antibodies comprising antibodies against human T cell receptor complex or human B cell receptor complex; autoimmune diseases |
| 01/31/2008 | US20080025978 High affinity ligand for p75 neurotrophin receptor |
| 01/31/2008 | US20080025977 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 01/31/2008 | US20080025976 Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| 01/31/2008 | US20080025975 Humanized antibodies against cd3 |
| 01/31/2008 | US20080025974 Toll-like receptor polypeptides for generating atibodies for use in treatment and prevention of septic shock, inflammation and viral infection |
| 01/31/2008 | US20080025973 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders |
| 01/31/2008 | US20080025972 Treating sex steriod responsive disorders |
| 01/31/2008 | US20080025971 Antibody comprising a human heavy chain framework sequence, three heavy chain hypervariable region sequences and three light chain hypervariable region sequences; modulating biological activity of integrins containing the beta7 subunit |
| 01/31/2008 | US20080025970 Treatment of atherosclerosis |
| 01/31/2008 | US20080025969 Treatment of Neurodegenerative Diseases by the Use of Gpr49 |
| 01/31/2008 | US20080025968 Methods and Agents for Immune Modulation and Methods for Identifying Immune Modulators |
| 01/31/2008 | US20080025967 Method and Kit for Detecting Proliferative Diseases Causing Sclerosis, Preventive and/or Remedy for Proliferative Diseases Causing Sclerosis and Method and Kit for Identifying Substance Efficacious in Preventing and/or Treating Proliferative Diseases Causing Sclerosis |
| 01/31/2008 | US20080025913 Novel Anti-Dc-Sign Antibodies |
| 01/31/2008 | CA2666515A1 Cancerous disease modifying antibodies |
| 01/31/2008 | CA2666464A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 01/31/2008 | CA2659353A1 Composition and method for treatment of tumors |
| 01/31/2008 | CA2659262A1 Improved vaccines and methods for using the same |
| 01/31/2008 | CA2659225A1 Immunogenic compounds and protein mimics |
| 01/31/2008 | CA2658952A1 Cellular receptor for antiproliferative factor |
| 01/31/2008 | CA2658713A1 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy |
| 01/31/2008 | CA2658180A1 Compositions for reprogramming a cell and uses therefor |
| 01/31/2008 | CA2657563A1 Post-translationally modified neurotrophins |
| 01/31/2008 | CA2619983A1 Fully human hybridoma fusion partner cell lines |
| 01/30/2008 | EP1882741A1 Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy |
| 01/30/2008 | EP1882697A1 Post-translationally modified neurotrophins |
| 01/30/2008 | EP1882696A2 PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays |
| 01/30/2008 | EP1882478A1 Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine |
| 01/30/2008 | EP1882035A2 Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy |
| 01/30/2008 | EP1881993A2 Nebulization of monoclonal antibodies for treating pulmonary diseases |
| 01/30/2008 | EP1881846A2 Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| 01/30/2008 | EP1881845A2 Nipah virus vaccines |
| 01/30/2008 | EP1881844A2 Vaccine composition comprising b-subunit of e.coli heat labile toxin and an antigen and an adjuvant |
| 01/30/2008 | EP1881843A2 Kinase peptides and antibodies |
| 01/30/2008 | EP1881838A1 Antitumor agent on the base of bcg vaccine, method for his preparation and its use |
| 01/30/2008 | CN101115846A Mammalian genes involved in infection |
| 01/30/2008 | CN101115836A Inhibiting her2 shedding with matrix metalloprotease antagonists |
| 01/30/2008 | CN101115772A Cytotoxic antibody directed against type-B lymphoid haematopoietic prolifeeations |
| 01/30/2008 | CN101115766A Codon-optimized HPV16LI for salmonella vaccine strains against human papillomavirus type 16 |
| 01/30/2008 | CN101115504A Minor allergen control to increase safety of immunotherapy |
| 01/30/2008 | CN101115503A Peptides for delivery of mucosal vaccines |
| 01/30/2008 | CN101115502A Vaccines against neisseria meningitidis |
| 01/30/2008 | CN101115501A Improvements relating to meningococcal outer membrane vesicles |
| 01/30/2008 | CN101115500A Compositions for immunizing against mycobacterium |
| 01/30/2008 | CN101115499A Combination of tyrosine kinase inhibitor and HER-2/NEU for cancer therapy |
| 01/30/2008 | CN101115494A Method of modulating vascularization |
| 01/30/2008 | CN101115472A Molecules enhancing dermal delivery of influenza vaccines |
| 01/30/2008 | CN101115468A Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion |
| 01/30/2008 | CN101113478A Method for diagnosing testicular seminomas |
| 01/30/2008 | CN101113178A Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (CTL) epitopes |
| 01/30/2008 | CN101113177A Method for separating and purifying anti-hepatitis B immune globulin from plasma or plasma component |
| 01/30/2008 | CN101113176A Method for preparing infectious chicken Fabricius bursa refined yolk cryodesiccation antibody |
| 01/30/2008 | CN101113167A Recombinant main outer membrane protein of chlamydi trachomatis and preparation method and application thereof |
| 01/30/2008 | CN101113166A Recombinant main outer membrane protein of Chlamydophila pneumoniae and preparation method thereof |
| 01/30/2008 | CN101113163A Hla-a24-restricted cancer antigen peptides |
| 01/30/2008 | CN101112621A PRRSV and PCV-2bivalent recombinant fowl pox virus disease live vector vaccines |
| 01/30/2008 | CN101112619A 疫苗组合物 Vaccine composition |
| 01/30/2008 | CN101112618A Vaccine composition |
| 01/30/2008 | CN101112617A Method for making new, branch and flow H9 sub-type tri-combined inactived vaccine |
| 01/30/2008 | CN101112616A Vaccine for the prophylactic or therapeutic immunization against HIV |
| 01/30/2008 | CN101112390A Joint production method for distilling immunopotentiator from waste blood |
| 01/30/2008 | CN100365120C Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/30/2008 | CN100365017C Antigenic polypeptide of chlamydia pneumoniae |
| 01/30/2008 | CN100364612C Degraded agonist antibody |
| 01/30/2008 | CN100364611C Peptide immunotherapeutic agent |
| 01/30/2008 | CN100364499C Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 01/30/2008 | CA2654911A1 Treatment of tumors in pediatric patients with epidermal growth factor receptor antagonists |
| 01/29/2008 | US7323557 Genome of the HIV-1 inter-subtype (C/B') and use thereof |
| 01/29/2008 | US7323548 Antibodies or active fragments specific for MORT-1 (Mediator of Receptor Toxicity) protein having amino acid sequence 2; tumors, hiv |
| 01/29/2008 | US7323546 Apoptosis-inducing polypeptides |
| 01/29/2008 | US7323440 De-immunized MOG (poly)peptide constructs |
| 01/29/2008 | US7323330 Genome sequences and nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells transformed by the vectors; kits for diagnosing infection and vaccines |
| 01/29/2008 | US7323311 Methods of obtaining a specific binding member that binds eotaxin |
| 01/29/2008 | US7323183 Vaccine compositions including chitosan for intranasal administration and use thereof |
| 01/29/2008 | US7323182 Oil in water emulsions containing saponins |
| 01/29/2008 | US7323181 Compositions and methods for WT1 specific immunotherapy |
| 01/29/2008 | US7323180 Use of cross-protection to identify novel vaccine candidates for infectious agents |
| 01/29/2008 | US7323179 Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
| 01/29/2008 | US7323178 vaccine based on the highly virulent EHV-1, ATCC Accession No. PTA-5789, against neurologic disease as well as respiratory disease and abortion, in an inactivated form |
| 01/29/2008 | US7323177 delivery vectors for antigen producing genes (heterologous gene sequences or fragments thereof) used to generate immune responses in commercial pigs; recombinant porcine adenovirus capable of expressing DNA of interest |
| 01/29/2008 | US7323175 Immunogenicity of glucan binding protein |
| 01/29/2008 | US7323174 Modulation of immune response and methods based thereon |
| 01/29/2008 | US7323173 Administration of phosphorylated Mammastatin having a molecular weight of 53 kDa or 49 kDa; the polypeptide is specifically reactive with monoclonal antibody 7G6 that is produced from hybridoma ATCC No. HB10152 |
| 01/29/2008 | US7323172 Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| 01/29/2008 | US7323171 less immunosuppression than pre-existing therapies; anti-LFA-3 antibody homologs, anti-CD2 antibody homologs, soluble LFA-3 polypeptides, small molecules, e.g., carbohydrates, soluble CD2 polypeptides, CD2 or LFA-3 mimetic agents and derivatives |
| 01/29/2008 | US7323170 Anti-CD80 antibodies |
| 01/29/2008 | US7323169 Sustained release formulations |
| 01/29/2008 | US7323168 Immunotherapy for chronic myelocytic leukemia |
| 01/29/2008 | CA2401295C Process for preparing an anti viral medicinal product from plant extracts |
| 01/29/2008 | CA2295321C Isolated nona- and decapeptides which bind to hla molecules, and the use thereof |
| 01/29/2008 | CA2264735C Neisseria meningitidis serogroup b glycoconjugates and methods of using the same |
| 01/25/2008 | CA2553402A1 Compositions for inhibiting sema7a and vla-1 interaction and methods of using the same |
| 01/24/2008 | WO2008011636A2 Targeted gene delivery for dendritic cell vaccination |
| 01/24/2008 | WO2008011609A2 Compositions and methods for vaccinating against hsv-2 |
| 01/24/2008 | WO2008011571A1 Polypeptides with reduced susceptibility to oxidation and methods of making |